The journey of innovation in cancer treatment begins with early drug development. ESMO TAT serves as a dynamic, multi-stakeholder forum, uniting researchers, industry leaders, investors, regulators, and patient advocates under one roof to accelerate the delivery of life-changing anticancer therapies to patients. Join us in the pursuit to advance cancer treatment: we look forward to seeing you at this transformative event, to share new data, foster collaboration, and tackle challenges that will drive early clinical development forward. Innovate. Collaborate. Advance.   Submit your abstract by 16 December 2025

Obesity remains a significant health concern, affecting over 17% of adults in Europe and contributing significantly to cancer development. The primary goal of the conference is to deepen our understanding of metabolic crosstalks and their profound implications for cancer. Taking a holistic approach, the event will explore the plethora of interactions between metabolism and cancer across various tissues and organs.
The conference will highlight key drivers stemming from unhealthy metabolism that impact cancer development. It will delve into cutting-edge topics such as advancements in adipocyte biology, uncovering the diverse roles of adipose tissue beyond fat storage and its influence on tumor metabolism. Additionally, groundbreaking research on exercise and its potential impact on cancer will be presented. The role of mitochondrial bioenergetics in metabolic regulation will be rigorously examined, offering promising avenues for cancer therapy. Moreover, the conference will scrutinize the tumor microenvironment and metabolic changes in surrounding tissues, alongside immune modulation, particularly in the context of obesity. Cachexia, a complex syndrome involving muscle wasting and its relationship with cancer, will also be a focal point.